About: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Creator	Banerjee, Shubhasree Biehl, Ann Hasni, Sarfaraz Schwartz, Daniella Massimo Gadina, •
topic	covid:277575898ce3b2eee6789233fc65d439c15858a2#this
source	PMC
abstract	The Janus kinase/signal transduction and activator of transcription (JAK–STAT) signaling pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Many cytokines involved in the pathogenesis of autoimmune and inflammatory diseases use JAKs and STATs to transduce intracellular signals. Mutations in JAK and STAT genes cause a number of immunodeficiency syndromes, and polymorphisms in these genes are associated with autoimmune diseases. The success of small-molecule JAK inhibitors (Jakinibs) in the treatment of rheumatologic disease demonstrates that intracellular signaling pathways can be targeted therapeutically to treat autoimmunity. Tofacitinib, the first rheumatologic Jakinib, is US Food and Drug Administration (FDA) approved for rheumatoid arthritis and is currently under investigation for other autoimmune diseases. Many other Jakinibs are in preclinical development or in various phases of clinical trials. This review describes the JAK–STAT pathway, outlines its role in autoimmunity, and explains the rationale/pre-clinical evidence for targeting JAK–STAT signaling. The safety and clinical efficacy of the Jakinibs are reviewed, starting with the FDA-approved Jakinib tofacitinib, and continuing on to next-generation Jakinibs. Recent and ongoing studies are emphasized, with a focus on emerging indications for JAK inhibition and novel mechanisms of JAK–STAT signaling blockade.
has issue date	2017-03-03(xsd:dateTime)
bibo:doi	10.1007/s40265-017-0701-9
bibo:pmid	28255960
has license	no-cc
sha1sum (hex)	277575898ce3b2eee6789233fc65d439c15858a2
schema:url	https://doi.org/10.1007/s40265-017-0701-9
resource representing a document's title	JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
has PubMed Central identifier	PMC7102286
has PubMed identifier	28255960
schema:publication	Drugs
resource representing a document's body	covid:277575898ce3b2eee6789233fc65d439c15858a2#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/277575898ce3b2eee6789233fc65d439c15858a2
is schema:about of	named entity 'autoimmune' named entity 'targeting' named entity 'rheumatoid arthritis' named entity 'autoimmune diseases' named entity 'phases' named entity 'JAK' named entity 'signaling' named entity 'SIGNALS' named entity 'STATS' named entity 'POLYMORPHISMS' named entity 'TARGETING' named entity 'AUTOIMMUNITY' named entity 'MOLECULE' named entity 'INHIBITION' named entity 'JAKS' named entity 'SIGNALING PATHWAY' named entity 'GENES' named entity 'INTRACELLULAR SIGNALING' covid:arg/277575898ce3b2eee6789233fc65d439c15858a2 named entity 'outlines' named entity 'success' named entity 'Tofacitinib' named entity 'rheumatoid arthritis' named entity 'JAK' named entity 'Janus kinase' named entity 'polymorphisms' named entity 'mechanisms' named entity 'targeted' named entity 'safety' named entity 'continuing' named entity 'indications' named entity 'JAK-STAT pathway' named entity 'JAK-STAT' named entity 'autoimmune diseases' named entity 'JAK-STAT' named entity 'intracellular signaling pathways' named entity 'pathogenesis' named entity 'rheumatologic disease' named entity 'signal transduction' named entity 'inflammatory diseases' named entity 'autoimmunity' named entity 'small-molecule' named entity 'JAKs' named entity 'activator of transcription' named entity 'cytokines' named entity 'autoimmune diseases' named entity 'Tofacitinib' named entity 'JAK-STAT' named entity 'Autoimmune Diseases' named entity 'psoriasis' named entity 'systemic lupus erythematosus' named entity 'STAT3' named entity 'phase IIa' named entity 'biological activity' named entity 'IL-15' named entity 'herpes zoster' named entity 'STAT6' named entity 'mutation' named entity 'Metabolism' named entity 'IL-6' named entity 'immune cells' named entity 'cytokines' named entity 'signaling molecules' named entity 'decernotinib' named entity 'DARWIN' named entity 'Crohn's disease' named entity 'Baricitinib' named entity 'maintenance dose' named entity 'cardiovascular events' named entity 'Baricitinib' named entity 'cytokine receptors' named entity 'elevated transaminases' named entity 'open trial' named entity 'small-molecule' named entity 'binding sites'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software